NRX PHARMACEUTICALS INC (NRXP) Stock Analyst Earnings Estimates
NASDAQ:NRXP - Nasdaq - US6294442099 - Common Stock - Currency: USD
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A 163.28% | N/A 187.67% | N/A 103.22% | N/A 108.00% | N/A 14.13% | N/A 12.77% | N/A 0.35% | ||||||||
| EBITDA YoY % growth | N/A | N/A | N/A | N/A | -94.428M | -44.331M 53.05% | -27.582M 37.78% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -134.5K | -1.007M -648.33% | -713.2K 29.14% | -907.4K -27.23% | -94.43M -10,306.66% | -44.335M 53.05% | -27.587M 37.78% | N/A 22.88% | N/A 210.22% | N/A 309.99% | N/A 276.30% | N/A 120.50% | N/A 124.67% | N/A 13.73% | N/A 12.71% | N/A 1.18% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | N/A | N/A | N/A | N/A | -4.00 39.04% | N/A 51.55% | N/A 91.40% | N/A 785.73% | N/A | N/A | N/A | N/A | N/A | N/A |
All data in USD
| Q4 / 24 | Q1 / 25 | Q2 / 25 | Q3 / 25 | Q4 / 25 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.32 35.40% | -0.41 44.86% | -0.22 66.51% | 0.26 296.15% | 0.38 216.84% |
| Revenue Q2Q % growth | 5.1M | 10.2M | 20.4M | 25.5M | |
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -4.862M -10.35% | -4.59M 23.47% | -2.346M 66.72% | 3.57M 218.13% | 5.1M 204.90% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2024 Q2Q % growth | -0.13 81.43% | -0.65 | 0.52 | 80.09% |
| Q2 2024 Q2Q % growth | -0.67 44.17% | -0.71 | 0.04 | 5.49% |
| Q1 2024 Q2Q % growth | -0.74 53.75% | -0.56 | -0.18 | -31.91% |
| Q4 2023 Q2Q % growth | -0.50 68.75% | -0.71 | 0.21 | 29.97% |
| Q3 2023 Q2Q % growth | -0.70 50.00% | -1.16 | 0.46 | 39.44% |
| Q2 2023 Q2Q % growth | -1.20 -9.09% | -1.39 | 0.19 | 13.92% |
| Q1 2023 Q2Q % growth | -1.60 -661.90% | -1.43 | -0.17 | -12.04% |
| Q4 2022 Q2Q % growth | -1.60 -1,677.78% | -1.48 | -0.12 | -8.18% |
| Q3 2022 Q2Q % growth | -1.40 -250.00% | -1.43 | 0.03 | 1.96% |
| Q2 2022 Q2Q % growth | -1.10 -189.47% | -1.02 | -0.08 | -7.84% |
| Period | Reported | Estimate | Difference | Surprise |
|---|
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 50.26% | 29.63% | 0% | 31.98% |
| Revenue | N/A | N/A | N/A | N/A |